Demetris Papamichael, Fiona Richards, Theresa Davis, Vasilis Aslanis, Etienne Chatelut, Kathryn Locke, Maurice L Slevin, Matt T Seymour
Total Page:16
File Type:pdf, Size:1020Kb
CURRICULUM VITAE Personal Details Surname Papamichael First Name Demetris Address Address (Home) 30, Melina Merkouri St., Engomi 2411, Nicosia, Cyprus (Work) 32 Acropoleos Ave., Strovolos 2006, Nicosia, Cyprus Telephone +35722-847402 (Sec.) +35799426245 (Mob.) e mail: [email protected] Nationality Hellenic Date of Birth 20.05.62 Marital Status Married with one daughter and one son Education Elenion (Primary School), Nicosia, Cyprus 1968-1974 Pancyprian Gymnasium (Secondary School), 1974-1980 Nicosia, Cyprus Served as second Lieutenant in the Cypriot army 1980-1982 Tank Corps (Conscription service) Medical School - Charing Cross and Westminster, 1982-1987 University of London Qualifications MB BS December 1987 MRCP (UK) 1992 CCST (UK) in Medical Oncology May 1998 FRCP (Lond.) May 2004 Present Director - Department of Medical Oncology Appointments Bank of Cyprus Oncology Centre May 1999 Hon. Associate Professor – St. George’s March 2015 Medical School University of London at the University of Nicosia Campus Bank of Cyprus Oncology Centre The Bank of Cyprus Oncology Centre was established in 1998 as an autonomous not-for profit specialized Cancer Centre, following an agreement between the Government of Cyprus and the Bank of Cyprus. Operational expenditure is covered by the Government and Capital expenditure by the Bank. It operates as a National referral centre and collaborates with both public and private hospitals for the diagnosis, treatment and management of cancer patients. In its 20 years of operation it has treated more than 38,000 patients. It receives an average of 200 new cancer cases a month, which represents about 75% of the total cancer incidence in Cyprus. It has state of the art facilities including three linear accelerators covering all national referrals for radiotherapy without a waiting list and a Chemotherapy Day Unit administering approximately 85 treatments / day. As the Director of Medical Oncology, I have been involved with the setting up and organization of the Cancer Centre from the outset. The Cancer Centre has achieved international accreditation back in 2007, and following regular reviews is maintained to date. The overall strategy of the Centre includes: attraction, development and retention of high calibre human resources, site specialisation of health professionals at the Centre, multidisciplinary collaboration with health professionals from private and public hospitals and voluntary organisations, operation of systems to assure quality and patient safety and to maintain the organisation on a learning and improving trajectory, undertaking of research and encouragement of health professionals to participate in scientific meetings and to publish, continuing education and training of those working at the Centre and of the collaborating health professionals, keeping abreast of changing technology through investment in new equipment and systems as well as through personal and professional development of all staff, employment of consultant grade medical staff only on salary and on five year revolving contracts which explicitly prohibit private work for personal gain. Prizes/Awards Aylwen Bursary - Awarded by the Joint Research Board / Special Trustees of St. Bartholomew’s Hospital, March 1996 Hans Wyder Fellowship - Awarded by the European Society for Medical Oncology (ESMO), June 1996 Clinical Training Fellowship - Awarded by the Joint Research Board / Special Trustees of St. Bartholomew’s Hospital, May 1997 American Society of Clinical Oncology (ASCO) - Merit Award May 1998 Research activities/portfolio Clinical Research Over the last fifteen years I have developed a special interest in the treatment of gastrointestinal malignancies. This is reflected in the clinical trial portfolio set out below as well as in my publication record. Participating or have participated in the following clinical trials as a P.I.: 1. MOSAIC – Randomised trial in the adjuvant therapy of colon cancer 2. PETACC-3 – Adjuvant therapy of colon cancer 3. Tirapazamine trial in advanced NSCLC 4. Randomised trial in advanced colorectal cancer – FOCUS – NCRI / Colorectal Cancer Trials Group – UK 5. Neoadjuvant therapy for stage III NSCLC – EORTC-LCG 6. Prophylactic Cranial Irradiation in Extensive SCLC – EORTC-LCG 7. Conventional vs Higher dose Prophylactic Irradiation for Limited SCLC – EORTC/LCG 8. Sequential use of Iressa in patients with metastatic NSCLC responding to first-line chemotherapy – EORTC-LCG 9. FOLFOX+Cetuximab vs FOLFIRI+Cetuximab, a randomized phase II study – CECOG 10. COIN B – NCRN-MRC / UK 11. FOLFIRI+sunitinib vs FOLFIRI+placebo – The “SUN” trial 12. A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for metastatic pancreatic cancer “VANILLA” study. 13. An open-label, randomized, controlled, multi-center, Phase 1/11 trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line treatment for subjects with k- ras wild type (WT) metastatic colorectal cancer (mCRC). “POSEIDON” trial. 14. A non-interventional follow-up to the MOSAIC study (multicentre international study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer) up to 10 years and translational research “MOSAIC EXTENSION”(C09-2) 15. A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (IMM- 101-002) 16. Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment. EORTC. 17. Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal cancer “SPECTAcolor” 18. A Prospective, Multicenter, Randomized, Double Blind, Placebo- controlled, 2-Parallel Groups, Phase 3 Study to compare the efficacy and safety of Masitinib in combination with Folfiri (Irinotecan, 5-Fluorouracil and Folinic Acid) to Placebo in combination with Folfiri In second line treatment of patients with Metastatic Colorectal Cancer 19. A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (MODUL) 20. A-REPEAT - Anti EGFR re-challenge and plasma genotyping of patients with advanced colorectal tumors. Teaching and educational activities - Involved in teaching for the European School of Oncology Courses (ESO). In addition, I have been involved in the organization of 3 ESO Masterclass courses in Cyprus. I am currently part of the ESO Faculty. - Teaching on the postgraduate course of the Hellenic Academy of Oncology, aimed at trainees in Medical Oncology from Greece and Cyprus. - Have been invited to give educational lectures at ESMO, ECCO and ESMO GI meetings on a number of occasions. - Recently, I have acquired the role of a Task Force leader for the International Society of Geriatric Oncology (SIOG), in order to develop guidelines for the management of older patients with colorectal cancer. This has culminated in recommendations that were initially published in 2099 and updated in 2013. - Member of the ESMO metastatic Colorectal Guidelines Group - ESMO faculty member for the Gastro-Intestinal Tumours Group - Member of the ESMO membership Committee - Teaching of Medical Students from St. George’s Hospital / Medical School (London) at the University of Nicosia Campus Membership of Professional and other Organisations European Society for Medical Oncology (ESMO) The Royal College Of Physicians - United Kingdom (RCP-UK) American Society of Clinical Oncology (ASCO) International Society of Geriatric Oncology (SIOG) Membership of Research and Educational Organisations National Cancer Research Network - UK – National Colorectal Cancer Trials Group European Organisation for Research and Treatment of Cancer – GI Group International Society For Geriatric Oncology (SIOG) Publications Citations: 9100 h-index: 21 1. Joel SP, Ellis P, O’Byrne K, Papamichael D, Hall M, Penson RT, Nicholls SE, O’Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M L. Therapeutic monitoring of continuous infusion etoposide in small cell lung cancer. J Clin Oncol 14(6):1903-1912, 1996 2. Papamichael D, Andrews T, Owen D, Carter M, Amess J, Lister TA, Rohatiner AZS. Intensive Chemotherapy for Adult Acute Lymphoblastic Leukaemia given with or without granulocyte / macrophage Colony Stimulating Factor. Ann Haematol 73 : 259-263, 1996 3. Papamichael D, Gallagher CJ, Oliver RTD, Johnson PW, Waxman J. Phase II study of Paclitaxel in pre-treated patients with locally advanced / metastatic cancer of the bladder and ureter. Br J Cancer 75: 606-607, 1997 4. J M Foran, J Apostolidis, D Papamichael, A J Norton, J Matthews, J A L Amess, T A Lister, A Z S Rohatiner. High dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 9 : 865-869, 1998 5. S Joel, K O’Byrne, R Penson, D Papamichael, A Higgins, H Robertshaw, R Rudd, D Talbot, M Slevin. A randomised concentration - controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer. Ann Oncol 9 : 1205-1211, 1998 6. M L Slevin, D Papamichael. Is there a standard adjuvant treatment for colon cancer? (Current Controversies in Cancer Section). Eur J Cancer 34: 1652- 1663, 1998 7. D Papamichael, N Amft,